Progyny, Inc. (PGNY) Stock Analysis

77.0/100
Buy Not Halal Healthcare
Price $36.18
Market Cap $2.66B
52-Week Change +48.16%

Is PGNY a good investment?

Progyny, Inc. (PGNY) has a Plutrex AI rating of 77.0/100 as of November 05, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: PEG of 0.87 vs. industry average 1.71 — PGNY is 49.4% cheaper per unit of growth than peers, paying a 53.7% P/E premium (32.70x vs. 21.27x) for 131.6% more long-term EPS growth (37.7% vs. 16.3% 5-year CAGR); this is the core value proposition. Main concern: Structural growth disconnect UNCHANGED: Revenue growth of 5.3% is structurally insufficient to sustain 37.7% 5-year EPS CAGR — the gap requires continued extraordinary margin expansion from already-leading margins (net margin 6.0% vs. peers 2.02%) or aggressive capital return; the deceleration from 101.5% historical YoY EPS growth to 17.5% projected next year suggests peak operating leverage is passing, making the 37.7% long-term projection increasingly dependent on revenue acceleration that is not yet evidenced.

Investment Summary

PGNY (Progyny) is a high-quality specialty fertility benefits manager trading at $30.10, up 8.6% from the prior report at $27.72. The core thesis remains intact: PEG of 0.87 (vs. industry average 1.71) signals PGNY is the most attractively priced growth stock in the Medical-Healthcare Plans peer group despite a P/E premium of 32.70x vs. peers at 21.27x. The fortress balance sheet (D/E of 0.05, $237M cash, $218M FCF) eliminates financial distress risk entirely. News flow is exceptional at 100/100 sentiment — record Q3 2026 revenue and profitability, 1.3 million new covered lives added in the latest selling season, and ongoing research publications reinforcing clinical differentiation. The stock's 8.6% run since the prior report has modestly stretched the entry zone and compressed the risk/reward from 2.32x to approximately 1.9x at current prices, warranting a slight reduction in the valuation rating and overall score. The investment remains a Buy but patient entry near support ($28.50–$30.50) is preferred to chasing after the recent run.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
98/100
Growth Potential
74/100
Valuation
65/100
Profitability
62/100
Debt Management
98/100
Analyst Sentiment
72/100
Technical Momentum
72/100
Insider Confidence
60/100
News Sentiment
96/100

Fundamental Analysis

PGNY delivers dominant sector profitability: operating margin of 11.41% is 186.8% above the industry average of 3.98%, net margin of 6.0% is nearly 3x the peer average of 2.02%, and gross margin of 24.57% is 73.1% above the industry's 14.19%. ROE of 16.24% exceeds the industry average of 11.02% by 47.4%, achieved without leverage (D/E of 0.05 vs. peer average 0.74). Free cash flow of $218M nearly matches the $237M cash balance, demonstrating exceptional cash conversion. The P/E of 32.70x is elevated in isolation but the PEG of 0.87 (sub-1.0 Buffett threshold) confirms growth-adjusted undervaluation using the 37.7% 5-year EPS CAGR. Revenue growth of 5.3% remains the structural concern — it barely exceeds peers (4.5%) and is fundamentally insufficient to sustain 37.7% EPS compounding without continued aggressive margin expansion. Historical EPS growth of 101.5% YoY is decelerating sharply to projected 17.5% next year, confirming the peak leverage period is normalizing. The analyst consensus target of $34.20 implies 13.6% upside from current levels, reduced from 23.4% at the prior report due to the stock's 8.6% appreciation.

News Sentiment

Progyny is having its moment. The specialty fertility and women's health benefits company delivered a record-breaking third quarter in 2026, posting both peak revenue and profitability that exceeded Wall Street estimates — a powerful one-two punch that underscores why employers keep choosing its platform over traditional healthcare plans. The headline numbers tell a compelling story: Progyny added a record 1.3 million new covered lives during the latest employer selling season, the kind of commercial momentum that rarely goes unnoticed on Wall Street. This isn't just growth — it's proof that the company's argument to cost-conscious employers is landing. In an era of rising medical costs, Progyny positions its evidence-based fertility and women's health management as a smarter way to control spending while improving employee outcomes. Beyond the financial fireworks, Progyny published new research this quarter examining racial and ethnic disparities in fertility treatment access and studying improvements in menopause symptoms through its managed care programs. These aren't just academic exercises — they reinforce the clinical credibility that sets Progyny apart from generic benefits administrators and strengthens the company's pitch to increasingly diversity-conscious corporate HR departments. With a conference appearance booked in San Diego through October 2026, the company is clearly on an investor roadshow footing. For everyday investors, the bottom line is straightforward: Progyny is winning clients, beating earnings estimates, and publishing science that justifies the premium its clients pay. The question is whether this momentum can translate into the revenue acceleration the stock's growth-adjusted valuation ultimately demands.

Risk Assessment

PRIMARY RISK: Revenue growth of 5.3% failing to accelerate means the 37.7% 5-year EPS CAGR is unsustainable without further margin expansion — net margins at 6.0% already vastly exceed peers at 2.02%, limiting the runway for continued margin-driven EPS beats. Any quarterly revenue miss or guidance cut would likely trigger rapid multiple compression from the elevated 32.70x P/E. SECONDARY RISK: The stock has rallied 8.6% since the prior report, compressing the analyst target upside from 23.4% to 13.6% and reducing risk/reward meaningfully. MITIGATION: The fortress balance sheet (D/E 0.05, $237M cash, $218M FCF) provides substantial downside protection — even if growth decelerates, the company generates exceptional cash and carries essentially no debt, limiting bankruptcy or distress risk. Stop-loss at $26.00 provides an ~11.9% buffer from the $29.50 midpoint, consistent with medium conviction sizing at 3.0% portfolio weight. The record 1.3M new covered lives adds real optionality to revenue reacceleration in 2027.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is PGNY a halal stock?

No, Progyny, Inc. (PGNY) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for PGNY?

Progyny, Inc. (PGNY) has a Plutrex AI rating of 77.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is PGNY a good investment?

According to Plutrex AI, PGNY has a Buy rating (77.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in PGNY?

US stocks like PGNY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in PGNY?

Plutrex AI identifies the main risks for PGNY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about PGNY

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open PGNY in ElBarake